CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America

From TechCrunch

By Theresa Loconsolo

September 30, 2026

Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America

Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America
Loading the player…

Spotify founder Daniel Ek’s Neko Health raised $700 million to build a business around scanning your body, but it’s not the only company centering its roadmap around a new kind of preventative healthcare. Midjourney is building its own body scanner, while Function Health has also raised significant capital to build out its preventative-health platform. Why are investors betting so big on this category? 

On this episode of TechCrunch’s Equity podcast, Dominic-Madori Davis talks with Farooq Abbasi, founder and general partner of Preface Ventures and an investor in Neko Health, about how Neko compares with other consumer-health startups. They discuss what has to happen for body scanning to become part of the broader healthcare system. 

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You can also follow Equity on X and Threads, at @EquityPod. 

View original article on techcrunch.com

Most Recent

AI voice startup ElevenLabs doubles valuation to $22B

The $300 million employee tender was co-led by Wellington and T. Rowe Price.

Sep 30, 2026

Restate lands $20M as the need for durable infrastructure increases with AI agents

Founded by Apache Flink veterans, the startup is taking on workflow heavyweight Temporal.

Sep 30, 2026

Charter Space raises $5M to bring insurance to the stars

As Charter explains on its website, a common experience for space companies is that regular insurers "heard a bunch of scary science words and freaked out."

Sep 30, 2026

a16z-backed EliseAI raises $350M, doubles valuation to $4B

EliseAI raises $350M, doubles valuation in a year.

Sep 29, 2026

Similar Posts

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York

The scanning and bloodwork health startup founded by Spotify's founder will officially launch in New York in about a month.

Aug 18, 2026

The biggest trends young NYC investors are bullish on — and why

As twenty-something-year-old investors enter the venture landscape, they bring fresh vibes and spot new trends that could become the next multibillion-dollar tech businesses. Already, we are seeing some young investors carving out new niches. Alex Chung, 26, is an investor at Chai Ventures. Her firm has backed companies like consumer health platform Unfabled and emotional well-being company MentalHappy. Chung says she’s taken an interest in how the broader ecosystem has reframed women’s health

Aug 26, 2024

Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

Women’s health company Evvy on Tuesday said it has raised a $40 million Series B led by Catalio Capital Management. Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, the company is best known for operating what it touts as the world’s only at-home CLIA-certified and CLEP-certified m

Sep 15, 2026